Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.64 |
| ▸ | CTSD | P07339 | 1/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.52 |
| ▸ | FCGRT | P55899 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972919 | 0.86 | F2 (0.55) | REN | |
| Neurokinin B SCHEMBL29390479 | 0.85 | GRPR (0.59) | — | |
| Neurokinin B SCHEMBL29440672 | 0.85 | GRPR (0.59) | — | |
| SCHEMBL30015314 | 0.82 | REN (0.53) | RENCTSDAGTR2AGTR1 | |
| SCHEMBL30350156 | 0.80 | TACR3 (0.57) | — | |
| SCHEMBL31332191 | 0.79 | F2 (0.58) | — | |
| SCHEMBL29419165 | 0.78 | OPRD1 (0.61) | — | |
| SCHEMBL22077026 | 0.78 | CALCR (0.59) | — | |
| SCHEMBL20639320 | 0.78 | CALCR (0.59) | — | |
| Deltorphin A SCHEMBL29789418 | 0.78 | REN (0.58) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-4514351-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | Kallyope, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211779-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. (US) | 2023-11-02 | — | — | WO | disclosed |